research use only
Cat.No.S5958
| Related Targets | PI3K Akt mTOR GSK-3 ATM/ATR DNA-PK PDPK1 PTEN PP2A PDK |
|---|---|
| Other AMPK Inhibitors | Dorsomorphin Dihydrochloride Dorsomorphin (Compound C) AICAR (Acadesine) A-769662 GSK621 WZ4003 ex229 (compound 991) Phenformin HCl BAY-3827 HTH-01-015 |
|
In vitro |
Water : 130 mg/mL
DMSO
: 26 mg/mL
(201.3 mM)
Ethanol : 26 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 129.16 | Formula | C4H11N5 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 657-24-9 | -- | Storage of Stock Solutions |
|
|
| Targets/IC50/Ki |
AMPK
JNK
p38 MAPK
|
|---|---|
| In vitro |
Metformin upregulates BAX activation with facilitation of BIM, BAD and PUMA, downregulates Bcl-2 and Bcl-xl, also induces cytochrome c release from mitochondria into the cytoplasm, directly triggering caspase-9-mediated mitochondrial apoptosis. |
| In vivo |
Metformin shows therapeutic effect of this compound in mouse model of liver fibrosis associated with nonalcoholic steatohepatitis (NASH) in which hepatic function, NASH lesions and fibrosis are improved. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05910554 | Not yet recruiting | Sarcoidosis Pulmonary |
University of Maryland Baltimore |
May 1 2024 | Phase 2 |
| NCT06120881 | Recruiting | Type 2 Diabetes |
University of California San Francisco|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
April 1 2024 | Early Phase 1 |
| NCT06147050 | Not yet recruiting | Long COVID |
Purpose Life Sciences |
April 2024 | Phase 3 |
| NCT06296836 | Not yet recruiting | Diabetes Mellitus Type 2 |
University of Illinois at Chicago|Emily Hanners|Dulal Bhaumik|Avisek Datta|Peggy Choye|Hailey Soni|Annesti Elmasri|Julie Jun|Colin Goodman |
April 1 2024 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.